These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 18516602)

  • 21. Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndromes.
    Wulfert M; Küpper AC; Tapprich C; Bottomley SS; Bowen D; Germing U; Haas R; Gattermann N
    Exp Hematol; 2008 May; 36(5):577-86. PubMed ID: 18439489
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
    Harada Y; Harada H
    J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathobiology, classification, and diagnosis of myelodysplastic syndrome.
    Mufti GJ
    Best Pract Res Clin Haematol; 2004 Dec; 17(4):543-57. PubMed ID: 15494293
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New agents in myelodysplastic syndromes.
    Jabbour EJ; Giles FJ
    Curr Hematol Rep; 2005 May; 4(3):191-9. PubMed ID: 15865871
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nuclear phospholipase C β1 signaling, epigenetics and treatments in MDS.
    Follo MY; Marmiroli S; Faenza I; Fiume R; Ramazzotti G; Martelli AM; Gobbi P; McCubrey JA; Finelli C; Manzoli FA; Cocco L
    Adv Biol Regul; 2013 Jan; 53(1):2-7. PubMed ID: 23058275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes.
    Kao JM; McMillan A; Greenberg PL
    Am J Hematol; 2008 Oct; 83(10):765-70. PubMed ID: 18645988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impaired mitochondrial gene transcription in myelodysplastic syndromes and acute myeloid leukemia with myelodysplasia-related changes.
    Schildgen V; Wulfert M; Gattermann N
    Exp Hematol; 2011 Jun; 39(6):666-675.e1. PubMed ID: 21447369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Myelodysplastic syndromes: preleukemic syndromes].
    Tassin F; Hermanne JP; Schaaf-Lafontaine N; Herens C; Thiry A; Paulus JM; Boniver J; Fillet G
    Rev Med Liege; 1998 Jun; 53(6):357-62. PubMed ID: 9713217
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overexpression of the novel oncogene SALL4 and activation of the Wnt/beta-catenin pathway in myelodysplastic syndromes.
    Shuai X; Zhou D; Shen T; Wu Y; Zhang J; Wang X; Li Q
    Cancer Genet Cytogenet; 2009 Oct; 194(2):119-24. PubMed ID: 19781444
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biology of myelodysplastic syndromes.
    Yoshida Y
    Int J Cell Cloning; 1987 Sep; 5(5):356-75. PubMed ID: 3305727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic indicators and scoring systems for predicting outcome in patients with myelodysplastic syndromes.
    Aul C; Giagounidis A; Heinsch M; Germing U; Ganser A
    Rev Clin Exp Hematol; 2004 Dec; 8(2):E1. PubMed ID: 16027099
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options.
    Niemeyer CM; Kratz CP
    Br J Haematol; 2008 Mar; 140(6):610-24. PubMed ID: 18302710
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Telomeres and telomerase in normal and leukemic hematopoietic cells.
    Engelhardt M; Wäsch R; Guo Y
    Leuk Res; 2004 Oct; 28(10):1001-4. PubMed ID: 15289009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic scoring systems for risk assessment in myelodysplastic syndromes.
    Greenberg PL; Sanz GF; Sanz MA
    Forum (Genova); 1999; 9(1):17-31. PubMed ID: 10101208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review.
    Bernasconi P
    Br J Haematol; 2008 Sep; 142(5):695-708. PubMed ID: 18540941
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Myelodysplastic syndromes].
    Garandeau C; Pautas E; Andreux M; Andreux J; Gaussem P; Siguret V
    Ann Biol Clin (Paris); 2000; 58(4):405-16. PubMed ID: 10932040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytogenetic aspects of adult primary myelodysplastic syndromes: clinical implications.
    Panani AD; Roussos C
    Cancer Lett; 2006 Apr; 235(2):177-90. PubMed ID: 15935553
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment strategies and issues in low/intermediate-1-risk myelodysplastic syndrome (MDS) patients.
    Bowen DT
    Semin Oncol; 2005 Aug; 32(4 Suppl 5):S16-23. PubMed ID: 16085013
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic tools in the indications for allogeneic stem cell transplantation in myelodysplastic syndromes.
    Bacher U; Haferlach C; Kröger N; Schnittger S; Kern W; Wiedemann B; Zander AR; Haferlach T
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):1-11. PubMed ID: 20053328
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of an activated JAK3 variant and a Xq26.3 microdeletion causing loss of PHF6 and miR-424 expression in myelodysplastic syndromes by combined targeted next generation sequencing and SNP array analysis.
    Kunze K; Gamerdinger U; Leßig-Owlanj J; Sorokina M; Brobeil A; Tur MK; Blau W; Burchardt A; Käbisch A; Schliesser G; Kiehl M; Rosenwald A; Rummel M; Grimminger F; Hain T; Chakraborty T; Bräuninger A; Gattenlöhner S
    Pathol Res Pract; 2014 Jun; 210(6):369-76. PubMed ID: 24674452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.